Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

National Lung Matrix Trial: Multi-drug, Genetic Marker-directed, Non-comparative, Multi-centre, Multi-arm Phase II Trial in Non-small Cell Lung Cancer

NCT02664935 is registered in ClinicalTrials.gov with University of Birmingham as lead sponsor.

NCT NCT02664935
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02664935 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
National Lung Matrix Trial: Multi-drug, Genetic Marker-directed, Non-comparative, Multi-centre, Multi-arm Phase II Trial in Non-small Cell Lung Cancer
Lead sponsor
University of Birmingham
Phase
Phase 2
Overall status
Completed
Start date
May 13, 2015
Completion date
November 29, 2023
Enrollment
423 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma, carcinoma, squamous cell, non-small cell lung cancer